GO
Loading...

Enter multiple symbols separated by commas

Biogen Inc

More

  • *Nike rises after results, outlook. March 20- U.S. stocks rose on Friday, pushing the Nasdaq to a 15- year high and helping the S&P 500 snap a three-week string of losses, following a pullback in the dollar, upbeat results from Nike and further biotech gains. Among early reporters, Nike jumped 3.7 percent to $101.98 as the biggest boost to the Dow after it posted a...

  • *Nike rises after results, outlook. March 20- U.S. stocks rose on Friday, pushing the Nasdaq to a 15- year high and helping the S&P 500 snap a three-week string of losses, following a pullback in the dollar, upbeat results from Nike and further biotech gains. Among early reporters, Nike jumped 3.7 percent to $101.98 as the biggest boost to the Dow after it posted a...

  • Why the massive biotech rally could continue Friday, 20 Mar 2015 | 4:24 PM ET

    Biotech stocks have been on fire. But these traders explain why the rally could still have legs.

  • These stocks are insulated from the rising dollar Friday, 20 Mar 2015 | 4:21 PM ET
    Biotech

    Biotechs and small caps are the top performers on Wall Street, with the health-care subsector up about 8 percent for the week.

  • Biotech stocks are looking crowded, expert says Friday, 20 Mar 2015 | 3:50 PM ET
    Biogen Idec employees work in the company’s manufacturing room.

    As the biotech sector and names such as Biogen continue to surge, finding value is becoming increasingly difficult, an expert says.

  • *Nike rises after results, outlook. March 20- U.S. stocks rose on Friday, putting the S&P 500 on track to snap a three-week streak of losses, following upbeat results from Nike, further gains in biotechs and a pullback in the dollar. Among early reporters, Nike jumped 4.8 percent to $103.02 as the biggest boost to the Dow after it posted a quarterly profit that beat...

  • *Wall St stocks rally; S&P set for weekly gain. *European stocks helped after Athens' assurances. NEW YORK, March 20- The U.S. dollar fell sharply on Friday and was on track for its biggest weekly decline against the euro in more than three years, helping to drive a rally in Wall Street stocks and crude oil.

  • Promising Alzheimer's drug   Friday, 20 Mar 2015 | 1:01 PM ET
    Man with Alzheimer

    Biogen will move its Alzheimer's drug quickly into phase 3 studies, jumping over the middle stage, reports CNBC's Meg Tirrell.

  • *Nike rises after results, outlook. March 20- U.S. stocks rose on Friday, lifted by results from Nike and another climb in biotechs, as investors assessed the impact of a stronger dollar on corporate profits. Nike jumped 4.5 percent to $102.77 as the biggest boost to the Dow after it posted a quarterly profit that beat market estimates.

  • March 20- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with...

  • Biogen Alzheimer's drug shows promise, shares up Friday, 20 Mar 2015 | 11:05 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    A Biogen Alzheimer's drug showed a significant slowing of the disease's hallmark cognitive declines.

  • *Nike climbs in premarket after results, outlook. March 20- U.S. stocks were poised for a higher open on Friday, with the S&P 500 on track to snap a three-week losing skid, buoyed by Nike earnings, as investors assessed the impact of a stronger dollar on corporate earnings. Dow component Nike's rose 5.2 percent to $103.42 in premarket after it posted a quarterly profit...

  • Biogen's stock gets boost from Alzheimer's results

    CNBC's Meg Tirrell reports the biotech company got better than expected results regarding its Alzheimer's drug.

  • Ahead: Short summer, go long Santa Friday, 20 Mar 2015 | 8:46 AM ET
    Janet Yellen speaking on March 18, 2015.

    History shows that after the Federal Reserve hikes rates for the first time, this happens to the stock market.

  • US STOCKS-Wall St stock futures rise after pullback Friday, 20 Mar 2015 | 7:32 AM ET

    *Biogen Idec shares were up 3 percent at $447 in premarket trading after its experimental drug became the first Alzheimer's treatment to significantly slow cognitive decline and reduce brain plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. *Tiffany& Co. shares were down 2.7 percent...

  • Biogen's Alzheimer's drug exceeds expectations   Friday, 20 Mar 2015 | 6:45 AM ET
    Biogen's Alzheimer's drug exceeds expectations

    CNBC's Meg Tirrell has the latest results on the biotech's Alzheimer's drug.

  • Biogen Alzheimer's drug: The results   Friday, 20 Mar 2015 | 5:40 AM ET
    Biogen Alzheimer's drug: The results

    CNBC's Meg Tirrell reports on Biogen's experimental drug for Alzheimer's and how the company appears to have exceeded expectations.

  • March 20- An experimental drug from Biogen Idec became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with expensive...

  • Moment of truth for Biogen's big Alzheimer's bet Thursday, 19 Mar 2015 | 12:55 PM ET
    alzheimer's

    As Biogen Idec gets set to reveal new data on its Alzheimer's drug, BIIB037, investors should be prepared for a big move either way.

  • *Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by Britain's health minister Jeremy Hunt at a meeting in Geneva on Tuesday, follows a Group of Eight nations conference in London in December 2013 that set a goal of finding a...